EP1187633A1 - Use of anti-vegf antibody to enhance radiation in cancer therapy - Google Patents

Use of anti-vegf antibody to enhance radiation in cancer therapy

Info

Publication number
EP1187633A1
EP1187633A1 EP00931923A EP00931923A EP1187633A1 EP 1187633 A1 EP1187633 A1 EP 1187633A1 EP 00931923 A EP00931923 A EP 00931923A EP 00931923 A EP00931923 A EP 00931923A EP 1187633 A1 EP1187633 A1 EP 1187633A1
Authority
EP
European Patent Office
Prior art keywords
vegf
cells
tumor
tumors
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931923A
Other languages
German (de)
French (fr)
Other versions
EP1187633A4 (en
Inventor
Ralph R. Weichselbaum
Donald W. Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of EP1187633A1 publication Critical patent/EP1187633A1/en
Publication of EP1187633A4 publication Critical patent/EP1187633A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • Tumors influence the surrounding host str ⁇ ma by inducing angiogenesis to supply their oxygen and nutrient needs, allowing them to grow.
  • angiogenesis is tightly associated with Tumors.
  • angiogenesis inhibitors are regulated by the balance between angiogenic nnd anti-ongiogenic fuc or$l ⁇ 2.
  • the induction of angiogenesis by tumor-derived pro-angiogcnic proteins is a discrete component of the malignant phcnotypc. Decreased production of angiogenesis inhibitors or increased
  • ungiogenic peptides can shiA the balance towards u pro-angiogcnic state*, permitting tumor growth.
  • a tumor increases in size, it disrupts its surrounding stro a and recruits still more host blood vessels. This paracrine relationship between a tumor and its blood supply represents a potential point of attack for an itumor therapy.
  • VEGF vascular cndothclial cell growth factor
  • VEGF-induced angiogenesis angiogenic in It is secreted by n wide variety of human tumors, and inhibition of VEGF- induced angiogenesis, either by neutralizing antibodies or a dominant negative soluble receptor,
  • VEGF vascular endothelial growth factor
  • Physiologic regulators of VEGF expression include hypoxia9 ⁇ l0 and cytokines ⁇ .
  • oncogcnic mutations of ras and p53 are associated with increases in intratumoral VEGF levels and a poor
  • the inve ⁇ .ioson provides a method of reducing tumor radio resistance or chemotherapy res.stance in a cancer patient being or to be treated with radiation or chemotherapy, by administering to the patient a substance that inhibits chemotherapy or rad t ation-induced VEGF expression or that blocks VEGF activity in the patient.
  • the substance can be an anti-VEGF antibody, and can be administered (preferably IV) shordy ( M hours) prior to chemotherapy or radiation treatment.
  • preferably is administered intravenously, either prior to, du ⁇ ng, or following radiation or chemotherapy administration.
  • FIGURE 1 VEGF levels in Lewis lung carcinoma in vivo and in vitro.
  • Cs were plated in six-well plates at low density (25% confluence), allowed to attach overnight, and then irradiated with 0, 5, ⁇ vi, or 20 Gy. Conditioned media was collected every 24 hrs, and cells were detached with trypsin and counted. VEGF levels were normalized to the number of cells and reported as total pg VEGF/10 6 cells. No VEGF was detectable in unconditioned media.
  • FIG. 1 VEGF expression in human tumor cell line*.
  • Subconflucnt cells from human tumor cell lines (Seg-1 esophageal adcnocarcinoma, SQ20B squamous cell carcinoma, Ul melanoma, and U87 and T98 glioblastoma) were exposed to 10 Gy of ioni ing radiation.
  • Conditioned media from radiated and unirradiaicd cells was collected 24 hours later.
  • VEGF levels in conditioned media were measured by EL1SA and normalized to cell number.
  • FIGURE 3 Effect of VEGF blockade prior to treatment with ionizing radiation in mouse tumors and human xcnografts. LLC cells (1 x 10 ⁇ ) were injected subcutancously into the hindlimbs of female C57B1 6 mice. SQ20B squamous cell carcinoma cells (5 x 10 6 ) and Scg-1 csophagca! adcnocarcinoma cells (3 xl O 6 ) were injccicd into the hindlimbs of female a l hymic nude mice.
  • Tumors were allowed lo attain a mean size between 350-450 mm -1 (LLC, 442 ⁇ 14 mm 3 ; SQ20B, 372 ⁇ 16 mm 3 ; Scg-1, 407 ⁇ 20 mm 5 ), after which treatment was begun.
  • LLC 350-450 mm -1
  • SQ20B 372 ⁇ 16 mm 3
  • Scg-1 407 ⁇ 20 mm 5
  • mice were administered inirapcritonualry 16 and 3 hrs before the first IR treatment and 3 hours before the second IR treatment (3 doses total); goat anti- mouse VEGF-164 antibody alone administered as described. Untreated controls received nonimmune goal IgG.
  • B Effect of VEGF blockade prior to ionizing radiation in SQ20B xenografts. Mice were treated as follows: IR, 40 Gy administered as four 10 Gy doses on days 0, 1 ,2, and 3; IR (40 Gy) plus monoclonal anti-human VEGF-165 antibody, 10 ⁇ g administered intrapcritoncally two to three hours before each dose of IR; monoclonal anti-human VEGF-165 antibody alone administered identically to the combined treatment group.
  • FIGURE 4 Effect of manipulating VEGF levels in vitro on rR * r ⁇ cdiatcd vascular endothclial cell killing.
  • MTT assays HUVECs were plated in 96-well plates al 1 x 103 cells/well and treated with either differing concentrations of rccombinant human VEGF-165 or monoclonal anti-human VEGF-165 antibody prior to treatment with IR, and abscrbancc readings measured at varying time points after IR (sec Methods).
  • clonogcnic survival assays For clonogcnic survival assays,
  • HUVECs were treated with different concentrations of VEGF or a polyelonal goat anti-VEGF-
  • HUVECs pretreated with a monoclonal anti-VEGF- 165 antibody prior to irradiation.
  • Ionizing radiation induces tumor VEGF production In vivo and in vitro
  • LLC cells (1 x 10*) were injected subcutancously in the hindlimbs of female C57BL/6 mice and allowed to grow to a volume of 510 ⁇ 11 mm'
  • VEGF levels were measured by ELIS ⁇ and normalized to total tumor protein. VEGF levels in extracts from control tumors remained relatively constant (46 to
  • Plasma VEGF levels remained low or undctcctablc in control and irradiated animals (data not shown).
  • VEGF mRNA levels were assessed in the same tumors by
  • VEGF transcripts were induced 3-fold two days after exposure to I (Fi ⁇ ure 1 A). Moreover, VEGF mP: ., levels remained elevated for fourteen days. These f i ndings demonstrate that IR induces VEGF expression in vivo.
  • VEGF levels in LLC-condiiioned media exhibited an IR dose-dependent increase within 24 hours.
  • VEGF expression was also studied in irradiated human tumor cell li nes: Seg-1 (esophageal adenocarcinoma)13 ; SQ20B (a radioresistant squamous cell carcinoma li foi e )14 ; Ul (melanoma); and T98 and U87 (glioblastoma). Under basal conditions, these tumor ceil lines secreted widely differing levels of VEGF, with U87 cells producing the most VEGF and Ul meianoma cells the .east ( Figure 2). All demonstrated an IR-dependem increase in VEGF production within 24 hours of treatment with 10 Gy ( Figure 2). These findings demonstrate that IR induces VEGF expression in diverse tumor cell types.
  • mice bearing LLC tumors (559 ⁇ 51 mm 3 ) were treated with a polyelonal goat antibody directed against recombinant murine VEGF-164 (R & D Systems, 10 ⁇ g qd by intrape ⁇ toneal injection) or with nonimmune goat IgG.
  • tumors from control animals had attained a volume of 2713 * 346 mm 3
  • SQ20B cells (5 x J 0 6 ) were implanted in the hindlimbs of female athymic nude mice and allowed to attain a volume of 372 ⁇ 16 mm 3 (Figure 3B), after which they were treated with IR alone (40 Gy given as four 10 Gy fractions), ami-VEGF antibody alone (10 ⁇ g inlraperitoneally each day for four doses), or combined IR and anti-VEGF antibody (10 ⁇ g antibody administered 3 hours prior lo treatment wilh IR). On day 19, tumors in untreated controls reached a mean volume of 3671 ⁇ 790 mm 3 .
  • Blocking VEGF increases cndothellal cell killing by ionizing radiation
  • IR growth blockade for endothelial cells
  • IR msy disrupt the paracrine relationship between the tumor and its blood supply and emphasizes the potential importance of combining an angiogenesis inhibitor with a DNA damaging agent.
  • IR is a major therapeutic modality that is effective in the treatment of relatively .mall tumors and of large tumors only with considerable toxicity to normal tissues. Depriving the tumor endothelium of VEGF using neutralizing antibodies prior lo IR exposure or pretreating tumor vessels with antiangiogcnic peptides represent strategics to increase the anti-tumor effects of IR with minimal toxicity to normal tissues.
  • Lewis lung carcinoma cells gifts of J. Folkman
  • SQ20B cells were grown as previously described 19.21.22.
  • Hurnan urnbilical vcin endothclial ⁇ ⁇ HUWECs were
  • Tumor volume was determined by direct measurement with calipers and calculated by the formula (length x width x depth 2) and reported as the mean volume ⁇ s.e.m., as previously described 19,21. Tumors were allowed ⁇ Q ⁇ t ⁇ Q ⁇ of m ⁇ QQ ⁇ ⁇
  • mice were divided into experimental groups and treatment begun.
  • Tumors were irradiated using a GE Maxitron X-ray generator operating at 150 kV, 30 mA, using a 1 mm aluminum fil t er at a dose ra t e of 188 cGy/min..
  • Mice were shielded with lead except for the t umor-bearing right hmdlimb. The care and treatment of animals was in accordance with institutional guidelines.
  • mice were chosen from each LLC experimental group such t ha t the overall group mean tumor volume was affected as little as possible and euthanized to ob t ain tumor t issue.
  • Tumor extracts were prepared by homogenizing tumors in RTP A buffer (150 mM Nad, 10 mM Tris, 5 mM EDT ⁇ , Triton -100 0.S%, and dithi 0 threitol 1 ⁇ M, P H 7.5, PMSF 50 ⁇ M, lcupcptin 1 ⁇ g/ml, and apro inin 2 ⁇ g/mi).
  • VEGF levels were measured in tumor extract supernatants by ELISA (R & D Systems), and protein assays were performed by Lowry assay. VEGF levels were normalized to total extract protein concentration and expressed as pg VEGF/mg total extract protein. VEGF levels in tumor cell conditioned media were also measured by ELISA and were normalized to cell number in each well. At least three wells per time point were measured. ⁇ - Ao
  • HUVECs and LCs were plated in EGM-2 media. Eighteen hours after plating, HUVEC media was replaced with media in which the VEGF supplied by the manufacturer was omitted, and a defined amount (0-50 ng/ml) of rccombinant VEGF-165 (R & D Systems, Inc.) had been added. Four hours later, cells were irradiated with doses of 0-900 cGy using , GE Maxitron X-ray generator operating at 250 kV, 26 mA, with a 0.5 mm copper filter at a dose rale r 1 18 cGy/min.
  • HUVECs were plated in serum-free EGM-2 containing 5 ng ml VEGF-165. Four hours before irradiation, polyelonal antibodies to human VEGF-165 (R & D Systems, Inc.) were added to the media. Media was replaced with serum- containing media 48 hours after IR and the cells incubated for colony counting.
  • PB VEGF PB VEGF (pg)
  • Tumor volume (% untreated control volume for untreated controls)
  • RNA was isolated from cultured cells and tumor tissue using the ⁇ uanidinc thiocyanate method23 utilizing Trizol Ls (Lifc ⁇ ⁇ 25 ⁇ g ⁇ ⁇ ⁇ ⁇ . ⁇
  • HUVECs were plated (1 x 10 1 cells/well in 96 well plates) in EGM-2 media and allowed to attach overnight. Media was replaced with EGM-2 media containing different concentrations of recombinant human vmV- 165 (R & D Systems, Inc.).
  • concentration of VEGF-165 was kept constant and varying concentrations of either a neutralizing polyelonal or monoclonal anti-human VEGF-165 antibody (R & D Systems, Inc.) were added prior to treatment with IR. 72 or 96 hours after IR, cells were pulsed with 3-[4. 5-
  • VEGF VascuJar cndotheJiaJ ⁇ factor.
  • Angiostatin a novel angiogenesis inhibitor that mediates the suppression of melas i ascs by a Lewis lung carcinoma. Cell 79, 315-328 (1994).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

We have discovered that VEGF expression is induced following exposure tumors to ionizing radiation (IR) both in vitro and in vivo. We found that treatment of tumor-bearing mice with a neutralizing antibody to VEGF prior to irradiation is associated with greater than additive antitumor effects.

Description

USE OF ANTI-VEGF ANTIBODY TO ENHANCE RADIATION IN CNACER THERAPY
BACKGROUND
This work was supported by grants rom the National Cancer Institute, and the
government have certain rights in the invention.
Tumors influence the surrounding host strαma by inducing angiogenesis to supply their oxygen and nutrient needs, allowing them to grow. In normal tissues, angiogenesis is tightly
regulated by the balance between angiogenic nnd anti-ongiogenic fuc or$lι2. However, the induction of angiogenesis by tumor-derived pro-angiogcnic proteins is a discrete component of the malignant phcnotypc. Decreased production of angiogenesis inhibitors or increased
expression of ungiogenic peptides can shiA the balance towards u pro-angiogcnic state*, permitting tumor growth. As a tumor increases in size, it disrupts its surrounding stro a and recruits still more host blood vessels. This paracrine relationship between a tumor and its blood supply represents a potential point of attack for an itumor therapy.
Λ family of angiogenic peptides, isofor s of vascular cndothclial cell growth factor (VEGF), are expressed by many human tumors and normal cells^-S, VEGF is the only known angiogenic protein that is exclusively itogenic for endothelial cells in vύro and strongly
angiogenic in It is secreted by n wide variety of human tumors, and inhibition of VEGF- induced angiogenesis, either by neutralizing antibodies or a dominant negative soluble receptor,
blocks the growth of primary and metastatic experimental tumors""". Physiologic regulators of VEGF expression include hypoxia9ιl0 and cytokines^. In certain human tumors, oncogcnic mutations of ras and p53 are associated with increases in intratumoral VEGF levels and a poor
nrcαr.csis' ^ >' ^.
' " ST τ\TM ARY OF THE INVENTION
In the present study, e examined the production of VEGF by L1X and human xcno graft tumors following exposure to ionizing radiation (IR), and found that VEGF expression is induced following IR- We next examined whether blocking the action of a positive regulator of angiogenesis could potentiate the αnutumor effect of IR.Block.ng this IR-mcdiatcd increase in VEGF using neutralizing antibodies against VF.GF resulted in increased cndotheϋal cell killing and produced greater than additive anti-tumor effect, in aousc tumor model systems, findings that support a model in which induction of VEGF by IR contributes to the protection of tumor blood vessels from radiation-mediated cytotoxicity.
The inveπ.io„ provides a method of reducing tumor radio resistance or chemotherapy res.stance in a cancer patient being or to be treated with radiation or chemotherapy, by administering to the patient a substance that inhibits chemotherapy or radtation-induced VEGF expression or that blocks VEGF activity in the patient.
The substance can be an anti-VEGF antibody, and can be administered (preferably IV) shordy (M hours) prior to chemotherapy or radiation treatment.
The dosages, fining, and duration of anti-VEGF antibody administration in
humans can be extrapolated from the antma! model results presented herem. Antibody
preferably is administered intravenously, either prior to, duπng, or following radiation or chemotherapy administration.
BRIEF DESCRIPTION OF THE PR AWTNrrς
FIGURE 1. VEGF levels in Lewis lung carcinoma in vivo and in vitro. A. VEGF mRNA levels in LLC tumors following IR exposure (40 Gy divided into two daily doses). Total RNΛ was isolated from representative tumors and probed with a cDNA encoding human VEGF- 165, after which they were stripped of probe and reprobed with a cDNA to GAPDH to demonstrate message integrity. By scanning densitomctry, normalized to GAPDH, VβGF mRNA is induced 3-fold following IR exposure. Blots from representative animals are displayed. B. VEGF protein levels in media conditioned by LLCs following ]R exposure. Cs were plated in six-well plates at low density (25% confluence), allowed to attach overnight, and then irradiated with 0, 5, ι vi, or 20 Gy. Conditioned media was collected every 24 hrs, and cells were detached with trypsin and counted. VEGF levels were normalized to the number of cells and reported as total pg VEGF/106 cells. No VEGF was detectable in unconditioned media.
Figure 2. VEGF expression in human tumor cell line*. Subconflucnt cells from human tumor cell lines (Seg-1 esophageal adcnocarcinoma, SQ20B squamous cell carcinoma, Ul melanoma, and U87 and T98 glioblastoma) were exposed to 10 Gy of ioni ing radiation. Conditioned media from radiated and unirradiaicd cells was collected 24 hours later. VEGF levels in conditioned media were measured by EL1SA and normalized to cell number. An increase in VEGF secretion was observed in each cell line: Scg-1 (p-?), SQ20B (p-0.08), T98 (p=0.02), Ul (p=0.009), U87 (p=0.0009). No VEGF was detectable in unconditioned media.
FIGURE 3. Effect of VEGF blockade prior to treatment with ionizing radiation in mouse tumors and human xcnografts. LLC cells (1 x 10δ) were injected subcutancously into the hindlimbs of female C57B1 6 mice. SQ20B squamous cell carcinoma cells (5 x 106) and Scg-1 csophagca! adcnocarcinoma cells (3 xl O6) were injccicd into the hindlimbs of female alhymic nude mice. Tumors were allowed lo attain a mean size between 350-450 mm-1 (LLC, 442 ± 14 mm3; SQ20B, 372 ± 16 mm3; Scg-1, 407 ± 20 mm5), after which treatment was begun. A. Effect of VEGF blockade prior to ionizing radiation in LLC tumors. Mice were treated as follows: IR, 40 Gy administered as two 20 Gy doses on days 0 and 1 ; IR (40 Gy) plus polyelonal goat anti-mouse VEGF-164 antibody. 10 μg were administered inirapcritonualry 16 and 3 hrs before the first IR treatment and 3 hours before the second IR treatment (3 doses total); goat anti- mouse VEGF-164 antibody alone administered as described. Untreated controls received nonimmune goal IgG. B. Effect of VEGF blockade prior to ionizing radiation in SQ20B xenografts. Mice were treated as follows: IR, 40 Gy administered as four 10 Gy doses on days 0, 1 ,2, and 3; IR (40 Gy) plus monoclonal anti-human VEGF-165 antibody, 10 μg administered intrapcritoncally two to three hours before each dose of IR; monoclonal anti-human VEGF-165 antibody alone administered identically to the combined treatment group. Untreated controls received nonimmune mouse IgG. C. Effect of VEGF blockade prior to ionizing radiation in Seg- 1. Mice were treated as follows: IR, 20 Gy administered as 4-5 Gy doses on days 0, 1,2, and 3; IR (20 Gy) plus monoclonal anti-human VEGF-165 antibody, 10 μg administered imraperitoneaily two to three hours before each dose of ]R; monoclonal ami-human VEGF-165 antibody alone administered identically lo the combined treatment group. Untreated controls received nonimmune mouse IgG. D. Mice bearing SQ20B xenografts from different treatment groups (day 22). Mice with tumor volumes closest to the mean for each group were chosen.
FIGURE 4. Effect of manipulating VEGF levels in vitro on rR*rπcdiatcd vascular endothclial cell killing. For MTT assays, HUVECs were plated in 96-well plates al 1 x 103 cells/well and treated with either differing concentrations of rccombinant human VEGF-165 or monoclonal anti-human VEGF-165 antibody prior to treatment with IR, and abscrbancc readings measured at varying time points after IR (sec Methods). For clonogcnic survival assays,
HUVECs were treated with different concentrations of VEGF or a polyelonal goat anti-VEGF-
] 65 antibody four hours prior to irradiation (sec Methods). A, MTT assay for HUVECs prctreaied with varying concentrations of recυmbinant human VEGF-165 four hours before IR treatment. Absorbance measurements were taken ai 96 hrs after IR and normalized to those obtained under standard conditions (no JR treatment and VEGF-10 ng/ml). B. Clυnogenic survival assay for HUVECs pretreated with 1, 10, or 50 ng/ml VEGF ± 200 and 900 cGy.
Surviving raction is normalized to plating efficiency for untrradiated cells. C. MTT assay for
HUVECs pretreated with monoclonal anti-VEGF-) 65 antibody four hours before IR treatment.
Absorbance measurements were taken at 96 hrs after IR and normalized to those obtained with no pretreatmenl with Ab. VEGF=10 ng/mlfor this experiment. D. Clonogcnic survival assay for
HUVECs pretreated with a monoclonal anti-VEGF- 165 antibody prior to irradiation.
DETAILED DESCRIPTION
Ionizing radiation induces tumor VEGF production In vivo and in vitro
We have examined the production of VEGF in Lewis lung carcinoma (LLC) tumors following exposure to ionizing radiation (IR). LLC cells (1 x 10*) were injected subcutancously in the hindlimbs of female C57BL/6 mice and allowed to grow to a volume of 510 ± 11 mm'
(approximately 2.5% body weight). Tumors were irradiated with 20 Gy on days 0 and 1 and then harvested at days 2, 5, or 14. VEGF levels were measured by ELISΛ and normalized to total tumor protein. VEGF levels in extracts from control tumors remained relatively constant (46 to
90 pg/mg total protein) for 14 days as the tumors grew to 6110 ± 582 mm3, or approximately
30% of body weight (Table I). By contrast, on day 2, the mean VEGF level in irradiated tumors was increased more than three-fold as compared to thai in uπirradiatcd tumors (234 ± 79 pg mg total extract protein, p=0,032). The mean VEGF level in irradiated tumors remained 2.2-foId higher than that in unirradiated tumors at day 14' (194 ± 47 pg/mg total extract protein, p-0.027).
Plasma VEGF levels remained low or undctcctablc in control and irradiated animals (data not shown). To confirm the effects of IR, VEGF mRNA levels were assessed in the same tumors by
Northern blol analysis. VEGF transcripts were induced 3-fold two days after exposure to I (Fiβure 1 A). Moreover, VEGF mP: ., levels remained elevated for fourteen days. These findings demonstrate that IR induces VEGF expression in vivo.
To determine whether IR induces VEGF in tumor cells in vitro, subconfluent LLC ceils were exposed lo different doses of IR, nd conditioned media was harvested at various intervals for measurement of VEGF levels by ELISA. VEGF levels in LLC-condiiioned media exhibited an IR dose-dependent increase within 24 hours. At 72 hours, VEGF levels were nearly 6-fold higher in media from LLC irradiated with 20 Gy (Figure IB), as compared to that for control cells (p=0.009). VEGF expression was also studied in irradiated human tumor cell lines: Seg-1 (esophageal adenocarcinoma)13; SQ20B (a radioresistant squamous cell carcinoma li„e)14; Ul (melanoma); and T98 and U87 (glioblastoma). Under basal conditions, these tumor ceil lines secreted widely differing levels of VEGF, with U87 cells producing the most VEGF and Ul meianoma cells the .east (Figure 2). All demonstrated an IR-dependem increase in VEGF production within 24 hours of treatment with 10 Gy (Figure 2). These findings demonstrate that IR induces VEGF expression in diverse tumor cell types.
Blocking VEGF action enhances the in vivo untitumor effect of ionizing radiation
To determine whether induction of VEGF secretion by tumors affects anti-tumor response, we treated LLC tumors with neutralizing antibodies to VEGF prior to IR exposure. Female C57B 6 mice bearing LLC tumors (559 ± 51 mm3) were treated with a polyelonal goat antibody directed against recombinant murine VEGF-164 (R & D Systems, 10 μg qd by intrapeπtoneal injection) or with nonimmune goat IgG. By day 7, tumors from control animals had attained a volume of 2713 * 346 mm3, while tumors in anti-VEGF-ireated mice were 101 1 _ 266 mm3 (p=0.02). Consistent with previous obWrv.tioM6.15-17 ^ Mngs indjωtc ^ blocking VEGF activity inhibits tumor growth. To evaluate the ami umor effects of combining anti-VEGF anlibodics and IR, mice bearing LLC tumors were treated as follows: untreated control; IR aiθne, 20 Gy on consecutive days (40 Gy total); anti-VEGF antibody; and IR plus anti-VEGF antibody (Figure 3Λ). Starting from a mean volume of 442 =fc 14 mm3 at day 0, tumors in untreated controls reached a mean volume of 1389 ± 136 mm3 by day 6. Treatment with anti-VEGF antibody alone produced a 42.6% reduction in tumor volume (796 ± 41 mm3, P=0.004); IR alone, 43.0% reduction (792 ± 30 mm\ p-0.006); and the combination of IR and Bnti-VEGF antibody, 78.0% reduction (305 * 58 mm3, p=0.001 relative to IR alone), a greater than additive effect (Table II).
To extend these findings to other models for tumors, we examined ihe effect of combining ami-VEGF antibody with IR in human squamous cell carcinoma and esophageal adcnocarcinoma xenografts, both of which represent human tumors for which IR is a major therapeutic modality. First, athymic nude mice bearing radioresistant human head and neck squamous cell carcinoma xenografts (SQ20B)H were treated iih IR and a neutralizing monoclonal antibody against human VEGF-165 (R & D Systems, inc.). SQ20B cells (5 x J 06) were implanted in the hindlimbs of female athymic nude mice and allowed to attain a volume of 372 ± 16 mm3 (Figure 3B), after which they were treated with IR alone (40 Gy given as four 10 Gy fractions), ami-VEGF antibody alone (10 μg inlraperitoneally each day for four doses), or combined IR and anti-VEGF antibody (10 μg antibody administered 3 hours prior lo treatment wilh IR). On day 19, tumors in untreated controls reached a mean volume of 3671 ± 790 mm3. Treatment with anti-VEGF antibody alone produced a 28.5% reduction in mean tumor volume (2624 ± 287 mm3); IR alone, a 48.8% reduction (1793 ± 279 mm3); and the combination of IR and anti-VKGF antibody, a 81.8% reduction (669 * 120 mm3, p=0.003 relative to IR alone). Next, we examined a xenogra t model for a human cancer that is seldom cured by IR alone, esophageal adcnocarcinoma. Seg-1 cells^ (3 x 106) wcrc implanted in the hindlimbs of athymic nude mice und allowed to attain α volume of 407 ± 20 mm3 (Figure 3C), after which ihey were treated with IR alone (20 Gy in daily 5 Gy fractions), anti-VEGF antibody as above, or combined therapy. Similar enhancement of the anutumor effect of IR by anli-VEGF antibody was observed. As was the case for LLC, in both human xenografts, the anti-tumor effects of combined therapy were greater than additive (Table 11). These findings suggest that blocking the effects of VEGF enhances the iimoricidal effects of IR.
Blocking VEGF increases cndothellal cell killing by ionizing radiation
To assess the potential effects of VEGF on IR-mediated killing of tumor cells and endothciia] cells, we measured in vitro survival of LLCs and human umbilical vein endothclial cells (HUVECs) following exposure to IR. By MTT assay, there was no delectable cytotoxicity of LLC or SQ20B cells following exposure to VEGF or anti-VEGF antibody (duta not shown). In addition, rccombinanl VEGF failed to protect LLC or SQ20B cells from IR-mediated killing (data not shown), and there was no interactive cytotoxicity of LLC when anti-VEGF antibody was combined with IR (data not shown). Next, the effect of exogenous VEGF protein on IR-
mediated cell killing of HUVECs was assessed by MTT^ and clonogenic assays*9 (Figure 4). As measured by the MTT assay 96 hours after IR, pretreatment with VEGF protected HUVECs against the cytotoxic effects of 10 Gy 111 in a dose-dependent fashion (Figure 4A-NKKD p VALUES). This effect was observed both in the presence and absence of serum (data not shown). Clonogenic survival was also increased in a dosc-dcpcndent fashion when VEGF was added to the HUVEC culture medium prior lo IR (Figure 4B). Next, we tested whether adding anti-VEGF increases endothclial cell sensitivity to I . Adding anti-VEGF anUbody to the culture medium prior to IR exposure decreased cell proliferation as measured by MTT assay in HUVECs but not SQ20B cells (Figure 4C) or LLC proliferation (data noi shown). Similar decreases in endothelial cell survival after exposure lo IR were obse,-ved in clonogcnic assays when HUVECs were pretreated with anti-VEGF antibody (Figure 4D). To determine whether VEGF protects against IR-induced apoptosis, flow cytometry studies were performed after labeling cells with 7-A AD» Thcrc was no dif c ^^ ^ ^^ ^^ ^
in HUVECs exposed to IR, concentrations of anti-VEGF monoclonal antibody as high as 100 ng/ml, or both IR and anti-VEGF antibody (DATA NEEDS TO BE FINALIZED). These results indicate that IR-induced VEGF production by tumors inhibits the lethal effects of IR on endothelial cells.
DISCUSSTON Our findings demonstrate that IR induces VEGF expression by tumors. Importantly, blocking the effect of VEGF in irradiated LLC and human tumors produces greater than additive antitumor effects /„ vivo. Also, blocking VEGF action produces increased clonogenic killing of vascular endothclial cells in vitro, whereas the addition of rccombinant VEGF blocks the killing of endothclial cells. Taken together, these data raise the possibility that blocking positive regulators of angiogenesis is effective in potentiating the antitumor effects of IR. The use of growth blockade for endothelial cells (anti-VEGF antibody) and IR msy disrupt the paracrine relationship between the tumor and its blood supply and emphasizes the potential importance of combining an angiogenesis inhibitor with a DNA damaging agent. IR is a major therapeutic modality that is effective in the treatment of relatively .mall tumors and of large tumors only with considerable toxicity to normal tissues. Depriving the tumor endothelium of VEGF using neutralizing antibodies prior lo IR exposure or pretreating tumor vessels with antiangiogcnic peptides represent strategics to increase the anti-tumor effects of IR with minimal toxicity to normal tissues.
METHODS
Cell culture
Lewis lung carcinoma cells (gift of J. Folkman) and SQ20B cells were grown as previously described 19.21.22. Hurnan urnbilical vcin endothclial ^ {HUWECs) were
maintained in EGM-2 medium (Clonetics) + 1% fetal bovine scrum (Clonetics). U87 and T98 human glioblastoma cells were maintained in RPMI-1640 (Life Technologies. Inc.) + 10% FBS (Intergen); Ul melanoma cells, DMEM (75%) + F12 (25%) + ] 0% FBS.
Neutralizing antibodies against VEGF
For experiments with LLC, neutralizing polyelonal goat antibody (IgG) against recombinant mouse VEGF-164 (R & D Systems, Inc.) was dissolved in PBS and administered via intrapcritoncal injection. Conlrol mice in these experiments received nonimmune goat IgG (Sigma). For experiments with human tumor xenografts, a neutralizing monoclonal antibody to recombinant human VEGF-165 (R & D Systems) was used. Control mice in these experiments received nonimmune mouse IgG (Sigma).
Tumor models
LLC cells were injected subcutaπeously into the right hind limb (1 X 106 cells in PBS) of C57BL 6 female mice (Frederick Cancer Research Institute). SQ20B human squamous cell
carcinoma cells" (1 x ,0* cells) and Seg-1 esophageal adenocarcinoma cells" (3 x 10' cells) were injected subcutaneously into the hind limb of female athymic nude mice (Frederick Cancer Research Institute). Tumor volume was determined by direct measurement with calipers and calculated by the formula (length x width x depth 2) and reported as the mean volume ± s.e.m., as previously described 19,21. Tumors were allowed {Q ^ tø Q ^^ of m^QQ ^ ^
which time mice were divided into experimental groups and treatment begun. Tumors were irradiated using a GE Maxitron X-ray generator operating at 150 kV, 30 mA, using a 1 mm aluminum filter at a dose rate of 188 cGy/min.. Mice were shielded with lead except for the tumor-bearing right hmdlimb. The care and treatment of animals was in accordance with institutional guidelines.
Measurement of VEGF levels in tumor extracts and conditioned media
At various time points, mice were chosen from each LLC experimental group such that the overall group mean tumor volume was affected as little as possible and euthanized to obtain tumor tissue. Tumor extracts were prepared by homogenizing tumors in RTP A buffer (150 mM Nad, 10 mM Tris, 5 mM EDTΛ, Triton -100 0.S%, and dithi0threitol 1 μM, PH 7.5, PMSF 50 μM, lcupcptin 1 μg/ml, and apro inin 2 μg/mi). The homogenate was then subjected to three freeze-thaw cycles in liquid nitrogen to lyse cells and then spun at 5000 G at 4« C lo pellet debris. VEGF levels were measured in tumor extract supernatants by ELISA (R & D Systems), and protein assays were performed by Lowry assay. VEGF levels were normalized to total extract protein concentration and expressed as pg VEGF/mg total extract protein. VEGF levels in tumor cell conditioned media were also measured by ELISA and were normalized to cell number in each well. At least three wells per time point were measured. Λ - Ao
P =
A rmur/tt "» in where P- proliferation relative to control; A= absorbance at 515 nm (Λs, ,); A0- A31J at T=0 hr, and Aeon^βAjw for control cells (unirradiated, grown in 10 ng/ml VEGP-165).
Clonogenic assays
Clonogenic assays were performed as previously described^. Briefly, HUVECs and LCs were plated in EGM-2 media. Eighteen hours after plating, HUVEC media was replaced with media in which the VEGF supplied by the manufacturer was omitted, and a defined amount (0-50 ng/ml) of rccombinant VEGF-165 (R & D Systems, Inc.) had been added. Four hours later, cells were irradiated with doses of 0-900 cGy using , GE Maxitron X-ray generator operating at 250 kV, 26 mA, with a 0.5 mm copper filter at a dose rale r 1 18 cGy/min. Cultures were returned to ihe incubator for 14-17 days, after which they were stained with crystal violet. Colonies were counted and surviving fractions were determined. Colonies containing >50 cells were scored as positive. For .ludies with antibodies, HUVECs were plated in serum-free EGM-2 containing 5 ng ml VEGF-165. Four hours before irradiation, polyelonal antibodies to human VEGF-165 (R & D Systems, Inc.) were added to the media. Media was replaced with serum- containing media 48 hours after IR and the cells incubated for colony counting.
Data analysis
Statistical significance was determined using one-way analysis of variance (ANOVA) or Student's t-test, as appropriate.
TΛflUSS AP TABLE LEGE DS TABLFf 1 : VEGF Levels In Lewis lung carcinoma rumors after irradiation
UNTREATED CONTROLS IONIZING RADIATION (40 Gy)
VEGF (PB VEGF (pg
Mean tumor volume VEGF/mg Mean tumor volume VEGF/mg total
Day (mm*) ± s.e.m total protein) (mm3) * g.e.m. rotein)
2 947 ± 43 69 ± 21 641 ± 22 234 ± 79
5 1545 ± 93 46 ± 18 786 ± 52 135 ± 32 * 14 6110 ± 582 90 ± 23 2854 ± 338 194 ± 47 *
*p < 0.05 relative to VEGF levels untreated controls
TABLE II: Effect of combining anti-VEGF antibody and Ionizing radiation
Tumor volume (% untreated control volume for untreated controls)
Expected for Observed
Ionizing Anti-VEGF combined If volume for Observed;
Tumor ay radiation antibody additive combined CXDCCtcd
LLC 6 57.0% 57.4% 32.7% 22.0% 0.673
Seg-1 13 19.8% 77.8% 15.4% 6.9% 0.448
SQ20B 19 51.2% 71.5% 36.6% 18.2% 0.497
Northern blots
Total RNA was isolated from cultured cells and tumor tissue using the βuanidinc thiocyanate method23 utilizing Trizol Ls (Lifc ^^ ^ 25 μg ^ ^ ^ ^.^
on 1.2% agarose gels containing formaldehyde and blotted onto nylon membranes, then hybridized with a cDNA probe labeled by random priming and consisting of a cDNA encoding
human VEGF** Hybridizations were carried out at 60* C in 0.5 M sodium phosphate (pH 7.0),
7% sodium dodecyl sulfate, 1 mM EDTA, and 1 % bovine serum albumin^, and blots were washed as previously escribed. After autoradiθβraph>, h]ot£ ^ ^.^ ^^ ^
rehybridized to a labeled cDN A encoding rat glyceraldchyde 3-pho.ph.te dchydrogcnasc (GΛPDH) to demonstrate message integrity.
MTTΛssays
HUVECs were plated (1 x 101 cells/well in 96 well plates) in EGM-2 media and allowed to attach overnight. Media was replaced with EGM-2 media containing different concentrations of recombinant human vmV- 165 (R & D Systems, Inc.). In odier experiments, the concentration of VEGF-165 was kept constant and varying concentrations of either a neutralizing polyelonal or monoclonal anti-human VEGF-165 antibody (R & D Systems, Inc.) were added prior to treatment with IR. 72 or 96 hours after IR, cells were pulsed with 3-[4. 5-
dimethylthiazol-2yl]-2, 5-dipheny!tetrazolium bromide (Sigma Chemical Company)18 at 0.5 mg/ml culture volume for four hours, after which the media was removed and the dye solubilized in dimethyl sulfoxide. Absorbance was measured at 515 nm and normalized to untreated control cells by the following equation: KEFKRENΓIΓK
1 - Hanahan, D., Christofori, G., Naik, P. & Arbeit, J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer 32A, 2386-2393 (1996).
2. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumori genesis. Cell 86, 353-364 (1996).
3. Fcrrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr Re n, 4-25 (1997).
4. Neufeld, G., Cohen, T., Gcngrinoviich. S. & PϋltoraJc, Z. VascuJar cndotheJiaJ ^ factor. (VEGF) and its receptors. FASE J 13, 9-22 (1999).
5. l"homas, K.A. Vεscular endothclial ' 8 crroowwtthn f Isarcttonrr, o a p ΛΛoftΛe«n.t and J se .lective angiogenic agent.
J. Biol. Chem. Ill, 603-606 (1996).
6. Λsano, M.. Yukita, A., MaUumol , T., Kαndo, S. & Suzuki, H. Inhibition of tumor βrowth and metastasis by an immunonc tralizing mϋnι,clϋnal amibody to human ^^ endothelial growth factor/vascular permeability factor-121 . Cancer Res. 55, 5296-5301 (1995).
7. Borgstrom, P.. Hillan. .J., Sriramarao, P. & Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endoihelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56, 4032-4039 (1996).
8- Goldman, C. . ,/ al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, mclasiasis, and mortality rate. Proc Natl Acad Sci USA 95, 8795-8800 (1998).
9. Levy, A.P., Levy, N.S. & Goldberg, M.A. Post-transcriptional reflation of vascular endothclial growth factor by hypoxia. .1 Biol Chem 271, 2746-2753 (1996). 10. Minchcnko, A., Bauer, T., Salccda, S. & Caro, J. Hypoxic stimulation of vascular endothelial growih factor expression in vitro and in vivo. Lab Invest 71, 374-379 (1994).
11. Kicscr, A., Weich, H. A., Brandncr, G., Marmc, D. & Kolch, W. Mutant p53 potentiates protein kinasc C induction of vascular endothclial growth factor expression. Oπcogene 9, 963-969 (1994).
12. Rak, J. et al. Mutant ras oncogencs uprcgulate VEGF/VPF expression: implications for induction and inhibition of lumor angiogenesis. Cancer Res 55, 4575-4580 (1995).
1 . Hughes, S.J. et al. Fas/APO-1 (CD95) is noi translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57, 5571-5578 (1997).
14. Wcichselbflum, R.R., Dahlberg, W. & Little, J.B. Inherently radioresistant cells exist in some human tumors. ProcNatl AcadSci USA 82, 4732-4735 (1985).
15. Kanai, T. et al. Anti-tumor and anii-metasiatic effects of human-vascular-cndothelial- growth-foctor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. IntJ Cancer 77, 933-936 (1998).
16. Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci USA 93, 14765-14770 (1996).
17. Asano, M. et al. Isolation and characterization of neutralizing monoclonal antibodies lo human vascular endothclial growth factor/vascular permeability factor] 21 (VEGF/VPF121). Hyhridoma 14, 475-480 (1995).
18. Carmichacl, J., DeGraff, W.G., Gazdar, Λ.F., Minna, J.D. & Mitchell, 13. Evaluation of a tetrazolium-bascd scmiauiomated colorimctric assay: assessment of radiosensitivity. Cancer Res 47, 943-946 (1987).
19. Mauceri, H. et al. Interaction of angiostatin and ionizing radiation in anti-tumour therapy. Nature 394, 287-291 (1998). 20. Philpou, N J. et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood VI, 2244-2251 (1996).
21. Gorski, D.H. et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58, 5686-5689 (1 98).
22. O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of melasiascs by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
23. Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal Biochem 162, 156-159 (1987).
24. Mukhopadhyay. D.. Kncbclmann. B., Cohen. H.T.. Ananth, S. & Sukhatme, V.P. The von Hippei-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17, 5629-5639 (1997).
25. Church, G.M. & Gilbert, W. Genomic sequencing. Proc Natl AcadSci USA 81, 1991- 3995 (1984).
26. Gorski, D.H. et al. Molecular cloning of a diverged homeobox gene that is rapidly down- regulated during the G,yG, irdnsilion in vascular smooth muscle cells. Mol Cell Biol 13, 3722-3733 (1993).

Claims

What is claimed:
1. Use of a substance that inhibits VEGF expression of blockers VEGF activity in vivo in the preparation of a medicament for the mediation of radio resistance or chemotherapy resistance in a human cancer patient.
2. The use of claim 1, wherein said substance is an anti-VEGF antibody.
EP00931923A 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy Withdrawn EP1187633A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12871399P 1999-04-08 1999-04-08
US128713P 1999-04-08
PCT/US2000/009255 WO2000061186A1 (en) 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy

Publications (2)

Publication Number Publication Date
EP1187633A1 true EP1187633A1 (en) 2002-03-20
EP1187633A4 EP1187633A4 (en) 2005-05-11

Family

ID=22436614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931923A Withdrawn EP1187633A4 (en) 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy

Country Status (3)

Country Link
EP (1) EP1187633A4 (en)
AU (1) AU4972900A (en)
WO (1) WO2000061186A1 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DE60313339T2 (en) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
DE60318089T2 (en) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
EP2033959B1 (en) 2003-12-20 2011-04-27 Merck Patent GmbH Tetrahydropyranoquinoline derivatives
ATE550019T1 (en) 2005-05-17 2012-04-15 Merck Sharp & Dohme CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
DE102005061840A1 (en) 2005-12-23 2007-06-28 Merck Patent Gmbh New polyaza-benzo-azulene compounds are transforming growth factor-beta receptor kinase inhibitors used for treating e.g. cancer, HIV infection and Alzheimer's disease
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007233237A1 (en) * 2006-03-29 2007-10-11 Genentech, Inc. Diagnostics and treatments for tumors
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (en) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
CN101679266B (en) 2007-03-01 2015-05-06 诺华股份有限公司 PIM kinase inhibitors and methods of their use
DE102007013856A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydropyrroloquinolines
DE102007013855A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydroquinolines
DE102007013854A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydroquinolines
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
DE102007047738A1 (en) 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
DE102007047737A1 (en) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidine and piperazine derivatives
DE102007047735A1 (en) 2007-10-05 2009-04-09 Merck Patent Gmbh thiazole
DE102007049451A1 (en) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
DE102008017853A1 (en) 2008-04-09 2009-10-15 Merck Patent Gmbh thienopyrimidines
WO2009129335A2 (en) 2008-04-15 2009-10-22 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
DE102008059578A1 (en) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-naphthyridine compounds
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EA201101399A1 (en) 2009-04-02 2012-08-30 Мерк Патент Гмбх HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS
JP5779172B2 (en) 2009-04-02 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Autotaxin inhibitor
ES2422718T3 (en) 2009-04-02 2013-09-13 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
JP6073677B2 (en) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Fused heterocyclic compounds and their use
DE102009033392A1 (en) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclic compounds as autotaxine inhibitors II
DE102009049211A1 (en) 2009-10-13 2011-04-28 Merck Patent Gmbh sulfoxides
JP5099731B1 (en) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション Substituted piperidines that increase p53 activity and uses thereof
CA2780111A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20120124469A (en) 2010-02-05 2012-11-13 메르크 파텐트 게엠베하 Hetaryl-[1,8]naphthyridine derivatives
AU2011217561B2 (en) 2010-02-22 2016-04-21 Merck Patent Gmbh Hetarylaminonaphthyridines
CA2793299A1 (en) 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylquinazolines
JP2013522292A (en) 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Indazole compounds and their use
CN102822171B (en) 2010-03-26 2015-09-02 默克专利有限公司 As the benzo naphthyridines amine of autotaxin inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
MX2012014549A (en) 2010-06-28 2013-02-07 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer.
DE102010025786A1 (en) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
CA2804285C (en) 2010-07-05 2019-05-14 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
DK2606134T3 (en) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA Interference-Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression by Short Interfering Nucleic Acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
DE102010035744A1 (en) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2011297961B2 (en) 2010-09-02 2015-07-02 Merck Patent Gmbh Pyrazolopyridinone derivatives as LPA receptor antagonists
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
MX2013010163A (en) 2011-03-09 2013-10-30 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses.
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2012166983A1 (en) 2011-05-31 2012-12-06 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
DE102011118830A1 (en) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (en) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Novel compounds that are erk inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (en) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopyridines substituted as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Prmt5 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORSKI D H ET AL: "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 15 July 1999 (1999-07-15), pages 3374-3378, XP002256383 ISSN: 0008-5472 *
LEE C G ET AL: "The effect of combined anti-VEGF mAb and radiation vs. radiation alone or anti-VEGF mAb alone on human tumor xenografts" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 200, XP001204640 & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999 ISSN: 0197-016X *
See also references of WO0061186A1 *

Also Published As

Publication number Publication date
EP1187633A4 (en) 2005-05-11
AU4972900A (en) 2000-11-14
WO2000061186A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
EP1187633A1 (en) Use of anti-vegf antibody to enhance radiation in cancer therapy
RU2294761C2 (en) Method for treating resistant human tumors with epidermis growth factor receptors antagonists
JP7342701B2 (en) Pharmaceutical composition for cancer treatment and/or prevention
Gorski et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
Crane Jr et al. Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon
EA023148B1 (en) Compositions of pd-1 antagonists and use thereof
Heyns et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events: Studies with vascular smooth muscle cells and endothelial cells
JP4076230B2 (en) Cancer treatment
KR20160093012A (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
CA2752890A1 (en) Method for preventing and treating hyperpermeability
CN113018438B (en) Application of CXCR2 inhibitor in preparation of medicine for treating nasopharyngeal carcinoma
KR20230065977A (en) Interferon-Based Methods and Pharmaceutical Combinations for Cancer Treatment
Bouchentouf et al. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction
Qin et al. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC‐160
WO2012108782A1 (en) Antibody that stops or slows tumour growth (variants)
AU2019392742A1 (en) Anti-cancer activity of adamantane derivatives
CN111419832B (en) Pharmaceutical composition and application thereof in preparation of tumor treatment drugs
Dong et al. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene
WO2021182572A1 (en) Medicament for treatment and/or prevention of cancer
Amagase et al. Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors
Ragnhammar et al. Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma
AU2007240946A1 (en) Treatment of melanoma
CN112569360A (en) Anti-tumor medicine composition based on blocking PD-1/PD-L1 and application thereof
JPH01126558A (en) Measurement of antibody dependant cellar cell poison
Amagase et al. Epidermal Growth Factor Prolongs Survival Time of Tumor‐bearing Mice

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050401

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF CHICAGO

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

17Q First examination report despatched

Effective date: 20060512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090514